Compare CMG & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMG | IQV |
|---|---|---|
| Founded | 1993 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Restaurants | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3B | 41.3B |
| IPO Year | 2005 | 2013 |
| Metric | CMG | IQV |
|---|---|---|
| Price | $34.12 | $171.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 16 |
| Target Price | $47.32 | ★ $230.56 |
| AVG Volume (30 Days) | ★ 13.8M | 2.7M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.70 | ★ 4.67 |
| EPS | 1.14 | ★ 7.84 |
| Revenue | ★ $11,925,601,000.00 | $9,739,000,000.00 |
| Revenue This Year | $9.78 | $6.76 |
| Revenue Next Year | $11.05 | $5.85 |
| P/E Ratio | $30.54 | ★ $21.95 |
| Revenue Growth | 5.41 | ★ 41.60 |
| 52 Week Low | $29.77 | $134.65 |
| 52 Week High | $58.42 | $247.05 |
| Indicator | CMG | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 32.62 | 39.16 |
| Support Level | $33.42 | $156.43 |
| Resistance Level | $35.14 | $193.26 |
| Average True Range (ATR) | 1.05 | 6.23 |
| MACD | -0.29 | 2.42 |
| Stochastic Oscillator | 9.73 | 48.15 |
Chipotle is a leading fast-casual, Mexican-inspired restaurant chain, generating $11.3 billion in sales across 3,644 company-operated US locations, 82 international units primarily in Canada and Europe, and three licensed stores operated with Alshaya Group in the Middle East at the end of 2024. The firm's revenue is primarily driven by food and beverage sales at its company-owned restaurants, supplemented by delivery fees generated through its first-party digital channels. Chipotle emphasizes ingredients with no artificial flavors and utilizes an efficient, assembly-line service model to serve mainly customizable burritos, bowls, salads, quesadillas, and tacos.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.